NBIX Stock — Neurocrine Biosciences Inc.: Cash, EV, Pipeline

Share price

$146.23

Market cap

$14,864.2M

Cash

$389.8M

Enterprise value

$14,474.4M

Balance sheet

Cash	$389.8M
Debt	$0.0M
Net cash	$389.8M
Enterprise value	$14,474.4M
Basic shares	101.6M shares
Fully diluted shares	101.6M shares
Fully diluted market cap	$14,864.2M
Cash per share	$3.84

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NBIX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	NBI-1065890	Phase 2	Tardive Dyskinesia	—
Aug 12 - Sep 23	NBI-1065845	Phase 3	Major Depressive Disorder	2027
Aug 12 - Sep 23	NBI-1065845	Phase 3	Major Depressive Disorder	2027
Aug 12 - Sep 23	NBI-1065845	Phase 3	Major Depressive Disorder	2027
Sep 12 - Oct 24	NBI-1117570	Phase 2	Schizophrenia	—
Nov 12 - Dec 24	NBI-1117568	Phase 3	Schizophrenia	—
Dec 13, 2027 - Jan 24, 2028	NBI-1117568	Phase 3	Schizophrenia	—
Mar 14 - Apr 25	NBI-1117568	Phase 2	Bipolar I Disorder; Mania	—
Apr 12 - May 24	Crinecerfont	Phase 2	Congenital Adrenal Hyperplasia	—
May 13 - Jun 24	Valbenazine	Phase 3	Chorea, Huntington	—
Aug 12 - Sep 23	NBI-1065845	Phase 3	Major Depressive Disorder	2027
Jun 12 - Jul 24	NBI-1065845	Phase 3	Major Depressive Disorder	2027
Aug 12 - Sep 23	NBI-1117568	Phase 3	Schizophrenia	—
Oct 18 - Nov 29	Crinecerfont	Phase 2	Congenital Adrenal Hyperplasia	—
Jan 12 - Feb 23	NBI-1117568	Phase 3	Schizophrenia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

INGREZZA

Approved · Active Modality: small molecule

Aliases Valbenazine

Target VMAT2

Partnerships Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma): royalties on net sales of valbenazine

Indications

Tardive dyskinesia (TD) (Approved)
Chorea associated with Huntington's disease (Approved)

Status note First FDA-approved drug for TD (launched May 2017) and for chorea associated with Huntington's disease (August 2023). Wholly-owned commercial product; facing ANDA generic challenge (Zydus FZE filed ANDA March 2025) and a DOJ civil investigative demand on INGREZZA sales/marketing (August 2025).

CRENESSITY

Approved · Active Modality: small molecule

Aliases Crinecerfont

Target CRF-1

Indications

Classic congenital adrenal hyperplasia (CAH) (Approved)
CAH in children aged 3 months to under 4 years (Phase 2)

Status note Launched in the U.S. as a first-in-class FDA-approved treatment for classic CAH; driving product sales growth. Phase 2 clinical study initiated to assess safety and tolerability in children aged 3 months to under 4 years with CAH.

VYKAT XR

Approved · Active Modality: small molecule

Target KATP channel

Partnerships Soleno Therapeutics: acquired May 2026 (VYKAT XR source)

Indications

Hyperphagia associated with Prader-Willi syndrome (Approved)

Status note Commercial product named alongside INGREZZA and CRENESSITY; indication not stated in the excerpts.

NBI-1117570

Phase 2 · Active Modality: small molecule

Target muscarinic M1/M4

Partnerships Nxera (formerly Sosei Heptares): 2021 collaboration and license agreement to develop and commercialize sub-type selective muscarinic M1/M4 compounds

Indications

Schizophrenia (Phase 2)

Status note Dual M1/M4 selective agonist in adults with schizophrenia; first patients dosed in a Phase 2 clinical study.

NBIP-2118

Phase 1 · Active

Target CRFR2

Status note Investigational corticotropin-releasing factor 2 receptor (CRFR2) agent; Phase 1 first-in-human clinical study initiated to evaluate safety and tolerability in adult participants. Indication not stated.

NBI-921352

Stage not disclosed · Active Modality: small molecule

Target Nav1.2/Nav1.6

Partnerships Xenon: 2019 collaboration and license agreement to identify, research, and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates

Indications

Epilepsy (Stage not disclosed)

Status note Investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6 in development as a potential treatment of certain types of epilepsy. Clinical stage not stated.

Elagolix

Approved · Active Modality: small molecule

Target GnRH receptor

Partnerships AbbVie Inc.: Neurocrine earns royalties on AbbVie net sales of elagolix

Indications

Endometriosis / uterine fibroids (AbbVie's ORILISSA) (Approved)

Status note AbbVie's commercial GnRH antagonist (ORILISSA); Neurocrine earns royalties on net sales reported in collaboration revenues.

Per-asset detail extracted from the 10-Q filed 2026-07-28. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NBI-1065845
Lead indication	Major Depressive Disorder
Lead phase	Phase 3
Active trials	18
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06786624	Phase 3	Recruiting	Sponsor	NBIX	—	Major Depressive Disorder	2027
NCT06911112	Phase 3	Recruiting	Sponsor	NBIX	—	Major Depressive Disorder	2027
NCT06963021	Phase 3	Recruiting	Sponsor	NBIX	—	Major Depressive Disorder	2027
NCT06963034	Phase 3	Recruiting	Sponsor	NBIX	—	Schizophrenia	—
NCT07105098	Phase 3	Recruiting	Sponsor	NBIX	—	Schizophrenia	—
NCT06312189	Phase 3	Enrolling by invitation	Sponsor	NBIX	—	Chorea, Huntington	—
NCT07196501	Phase 3	Recruiting	Sponsor	NBIX	—	Major Depressive Disorder	2027
NCT06966401	Phase 3	Recruiting	Sponsor	NBIX	—	Major Depressive Disorder	2027
NCT07227818	Phase 3	Recruiting	Sponsor	NBIX	—	Schizophrenia	—
NCT07114874	Phase 3	Recruiting	Sponsor	NBIX	—	Schizophrenia	—
NCT04806451	Phase 3	Active, not recruiting	Sponsor	NBIX	—	Congenital Adrenal Hyperplasia	—
NCT04490915	Phase 3	Active, not recruiting	Sponsor	NBIX	—	Congenital Adrenal Hyperplasia	—

Sponsor-matched active trials from ClinicalTrials.gov (18 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 21 active trials for Neurocrine Biosciences on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	1,267,925	+205,853	1.82%	2026-08-14
Braidwell LP	336,171	-315,950	2.10%	2026-08-14
ADAR1 Capital Management	0	-2,500	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NBIX — Neurocrine Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders